European Pot Firm Valued at $190 Million in New Funding Round
- EMMAC Life Sciences raising money via convertible loan note
- Firm recently launched CBD-infused muscle gel with Boots
This article is for subscribers only.
One of Europe’s crop of cannabis companies was valued at 150 million pounds ($190 million) in its most recent funding round, reflecting rising industry growth as well as investor appetite, despite a murky regulatory picture.
London-based EMMAC Life Sciences Ltd. raised 15 million pounds through a convertible loan note, pitched at a conversion price of 50 pence per share, it said in a press release viewed by Bloomberg News. It didn’t disclose the names of any investors.